Oral contraceptives in women with systemic lupus erythematosus [9]

New England Journal of Medicine

Volumn 354, Issue 11, 2006, Pages 1203-1204

  Schwarz, Eleanor B ^a   Lohr, Patricia A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CONTRACEPTIVE AGENT; LEVONORGESTREL;

CONTRACEPTION; FEMALE; FOOD AND DRUG ADMINISTRATION; GENITAL TRACT INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAUTERINE CONTRACEPTIVE DEVICE; LETTER; PREGNANCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; WORLD HEALTH ORGANIZATION;

CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; INFECTION; INTRAUTERINE DEVICES; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK;

EID: 33644985962     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060035     Document Type: Letter

References (5)

1. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
2. Trussell J. Contraceptive failure in the United States. Contraception 2004;70:89-96.
3. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-49.
4. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
5. Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. Lancet 1998;351:1005-8.